The Food and Drug Administration (FDA) moved last week to fast-track an mRNA vaccine candidate for a type of avian influenza, or bird flu, that has sickened more than 70 Americans this year, according to the company that developed the vaccine.
Arcturus Therapeutics said in an April 10 statement that the vaccine, ARCT-2304, is now in its Phase 1 trials.
“We are pleased to receive fast-track designation from the FDA for ARCT-2304,” Joseph Payne, the CEO of Arcturus Therapeutics, said in the statement. “We remain steadfast in our commitment to the US government to develop safe and effective … next-generation mRNA vaccines to protect US citizens from future pandemic threats. This designation from the FDA is an important step forward in our mission to provide protective solutions for global health crises.”…